Yuka Ito, Masahiko Mori, Yuki Matsumoto, Taro Okamoto. Show Affiliations »
Abstract
Entities: Chemical Disease Gene
Mesh： See more » Administration, OralAnimalsClinical Trials as TopicDiabetes Mellitus, Type 2/drug therapyDipeptidyl-Peptidase IV Inhibitors/administration & dosageDipeptidyl-Peptidase IV Inhibitors/pharmacokineticsDipeptidyl-Peptidase IV Inhibitors/pharmacologyDrug Administration ScheduleDrug EvaluationDrug Evaluation, PreclinicalHeterocyclic Compounds, 2-Ring/administration & dosageHeterocyclic Compounds, 2-Ring/pharmacokineticsHeterocyclic Compounds, 2-Ring/pharmacologyHumansHypoglycemic AgentsIn Vitro TechniquesMicePyrans/administration & dosagePyrans/pharmacokineticsPyrans/pharmacology
Substances： See more » 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amineDipeptidyl-Peptidase IV InhibitorsHeterocyclic Compounds, 2-RingHypoglycemic AgentsPyrans
Year: 2017 PMID： 28260743 DOI： 10.1254/fpj.149.128
Source DB: PubMed Journal: Nihon Yakurigaku Zasshi ISSN： 0015-5691